spacer
home > pmps > winter 2010 > taming volatility
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taming Volatility

The abatement of volatile organic compound (VOC) emissions is compulsory in most global regions today, with corporate, international and regional legislative drivers in place, and action triggered by the quantity of solvents and types that a process uses. Emission limits may vary according to regional legislation, although the use of chlorinated and risk phrase compounds (R40, R45, R46, R49, R60 and R61) generally demand more stringent abatement criteria.

The selection of an abatement solution often involves the review of a number of options, involving iterations considering criteria such as VOC removal efficiency, energy use, off gas generation, sensitivity to solvent types, future process changes, as well as ensuring the selection satisfies best available technology (BAT), a key requirement of legislation.

In the pharmaceutical manufacturing sector, dealing with emissions from a variety of sources is commonplace, whether it be from a primary manufacturing process, such as bulk reactor emissions with small flows of highly intermittent, concentrated, often nitrogen-blanketed emissions, or from secondary operations such as tablet coating and packaging, where flows are generally in air, have larger volumes, with insolvent air concentrations in the range of 1 to 25 per cent lower explosive limit (LEL) and emitting hours being in the thousands per annum. It is one of these secondary processes of tablet coating that will be discussed here.

TABLET COATING OPERATIONS

If we take a tablet coating operation, the solvents used may carry fillers and coating compounds applied to achieve specific medication release characteristics, as well as either using single or multiple solvents throughout the coating process. Gathering data on solvent type, use and process conditions is key to achieving a refined abatement solution that will not affect the process or overburden costs of operation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin Jones has a degree in Mechanical Engineering and has worked in the air pollution and environmental industries for 20 years, with experience in supplying and engineering turnkey abatement systems for general industrial, chemical, pharmaceutical, petrochemical, ethanol production and printing industries. He also has broad experience in the provision of front-end design studies and solution reviews, process interface scheme designs, secondary energy production, pilot studies, turnkey installation and project management. Email: kjones@megtec.co.uk
spacer
Kevin Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the 11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement